-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
G1 Therapeutics, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q1 2019 to Q2 2024.
- G1 Therapeutics, Inc. Income Tax Expense (Benefit) for the quarter ending June 30, 2024 was $0.000, a 100% decline year-over-year.
- G1 Therapeutics, Inc. Income Tax Expense (Benefit) for the twelve months ending June 30, 2024 was $1.81M, a 39.9% decline year-over-year.
- G1 Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2023 was $3.12M, a 83.2% increase from 2022.
- G1 Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2022 was $1.7M, a 83.8% increase from 2021.
- G1 Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2021 was $925K, a 34.4% decline from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)